anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Understanding disease transmission in the workplace is essential for protecting workers. To model disease outbreaks, the small populations in many workplaces require that stochastic effects are considered, which results in higher uncertainty. The aim of this study was to quantify and interpret the uncertainty inherent in such circumstances. We assessed how uncertainty of an outbreak in workplaces depends on i) the infection dynamics in the community, ii) the workforce size, iii) spatial structure in the workplace, iv) heterogeneity in susceptibility of workers, and v) heterogeneity in infectiousness of workers. To address these questions, we developed a multiscale model: A deterministic model to predict community transmission, and a stochastic model to predict workplace transmission. We extended this basic workplace model to allow for spatial structure, and heterogeneity in susceptibility and infectiousness in workers. We found a non-monotonic relationship between the workplace transmission rate and the coefficient of variation (CV), which we use as a measure of uncertainty. Increasing community transmission, workforce size and heterogeneity in susceptibility decreased the CV. Conversely, increasing the level of spatial structure and heterogeneity in infectiousness increased the CV. However, when the model predicts bimodal distributions, for example when community transmission is low and workplace transmission is high, the CV fails to capture this uncertainty. Overall, our work informs modellers and policy makers on how model complexity impacts outbreak uncertainty. In particular: workforce size, community and workplace transmission, spatial structure and individual heterogeneity contribute in a specific and individual manner to the predicted workplace outbreak size distribution.
Implementations generally relate to monitoring the health condition of a television user. In some implementations, a method includes detecting one or more activities of a user, wherein the one or more activities include watching television. The method further includes monitoring one or more health vitals of the user. The method further includes tracking a health status of the user based on the one or more activities and based on the monitoring of the one or more health vitals. The method further includes detecting one or more health anomalies based the health status. The method further includes responding to the one or more health anomalies based on one or more predetermined policies.
According to recent research, inflammatory STAT4 and its protein impact may be important factors in developing cancerous diseases. Still unanalyzed is this effect in patients with laryngeal squamous cell carcinoma (LSCC). In the present study, we evaluated four single nucleotide variants (SNVs) of STAT4 (rs10181656, rs7574865, rs7601754, and rs10168266) and STAT4 serum levels to determine their link between LSCC development and its clinical manifestations. A total of 632 men (324 LSCC patients and 338 healthy individuals) were involved in this study. The genotyping was carried out using real-time PCR. Additionally, we measured 80 study subjects' (40 LSCC patients and 40 control subjects) STAT4 protein concentrations using an enzyme-linked immunosorbent assay (ELISA). In our study, the T allele of STAT4 rs7574865 significantly increases the likelihood of LSCC occurrence by 1.4-fold. Additionally, this SNV is associated with higher odds of early-stage disease, T1 size LSCC development, absence of metastasis to neck lymph nodes, and well-differentiated carcinoma. The G allele of rs10181656 is significantly associated with various clinical characteristics of LSCC, increasing the odds of early- and advanced-stage disease by 2.8-fold and 1.9-fold, respectively. Additionally, this allele is linked to an increased likelihood of developing tumors of different sizes and non-metastasized LSCC, as well as poorly differentiated carcinoma, highlighting its potential impact on the development and features of LSCC. Conclusion: The analysis of the STAT4 rs7574865 SNV revealed that the G allele is linked to a more favorable prognosis in LSCC. Additionally, it is hypothesized that the G allele of rs10181656 may be associated with the occurrence of LSCC but may not serve as a sensitive prognostic biomarker for distinguishing between disease stages, cell differentiation, or tumor size.
PURPOSE:To provide the titled remedy containing a specific compound as active component having vitamin B1 activity, penetrable deep into the skin, decomposable in the body to form a strong microbicidal substance and free from side effect such as skin irritation, development of red spot, etc. CONSTITUTION:The compound of formula (R1 is methyl, ethyl, propyl, etc.; R2 is methyl, ethyl, allyl, etc.), its hydrochloride or nitrate is used as a remedy for bacterial dermatosis such as athlete's foot. The compound of formula is decomposed into thiamine and an alkyl sulfide in the body to exhibit strong microbicidal effect and imparts strong effect against the microorganism living in the deep part of the skin. The compound of formula is an epoch-making remedy having chemical stability, free from side effect such as skin irritation or development of red spot and acting as a useful vitamin B1 when absorbed in the body.
<P>PROBLEM TO BE SOLVED: To provide a purified and modified phytase enzyme derived from Escherichia coli K12 appA phytase.  <P>SOLUTION: The present invention relates to a newly identified polynucleotide, a polypeptide encoded by the polynucleotide, uses of the polynucleotide and polypeptide as well as production and isolation of the polynucleotide and polypeptide. More specifically the polypeptide is an enzyme having phytase activity. The enzyme has improved thermal tolerance as compared with a wild-type enzyme. In addition, the enzyme exhibits improved protease stability at a low pH. Glycosylation of the modified phytase gives improved thermal tolerance and protease stability. The enzyme can be produced from native or recombinant host cells and can be used to help the digestion of phytic acid where desired. In particular, the enzyme can be used in foodstuffs to improve the feeding value of phytic acid rich ingredients.  <P>COPYRIGHT: (C)2008,JPO&INPIT
The invention provides a method for extracting Humulus scandens (Lour.) Merr. leaf protein and total flavonoids in a graded manner simultaneously from fresh and tender stems and leaves of Humulus scandens (Lour.) Merr.. The method comprises the steps as follows: firstly, the stems and the leaves of the Humulus scandens (Lour.) Merr. are obtained, the water content and the wet weight are measured after the stems and the leaves are washed and dried by airing, and the stems and the leaves are cut into slices; then distilled water is added for homogenization, press filtration is performed after homogenization to obtain Humulus scandens (Lour.) Merr. juice and filter cakes; the Humulus scandens (Lour.) Merr. juice is subjected to heating, alkaline precipitation and centrifugation to obtain a supernatant liquid and deposits, the deposits are frozen and dried so as to obtain the Humulus scandens (Lour.) Merr. leaf protein; then the filter cakes and the supernatant liquid are mixed, extraction is performed under an alkaline condition, acid precipitation and centrifugation are performed, and after obtained deposits are washed by water, dissolved in alcohol and subjected to suction filtration, a filtrate is concentrated, dried and frozen so as to obtain the Humulus scandens (Lour.) Merr. total flavonoids. According to the method, the Humulus scandens (Lour.) Merr. leaf protein and the Humulus scandens (Lour.) Merr. total flavonoids are extracted in the graded manner simultaneously in one technological process, so that the method is convenient to operate, accurate and reliable in extraction technological condition and high in yield and purity, two important effective components, namely, the leaf protein and the total flavonoids, in the Humulus scandens (Lour.) Merr. can be developed and utilized simultaneously, and development and utilization values of Humulus scandens (Lour.) Merr. resources are increased.
The pathogenic mechanisms contributing to neurological disability in progressive multiple sclerosis (PMS) are poorly understood. Cortical neuronal loss independent of cerebral white matter (WM) demyelination in myelocortical MS (MCMS) and identification of MS patients with widespread cortical atrophy and disability progression independent of relapse activity (PIRA) support pathogenic mechanisms other than cerebral WM demyelination. The three-dimensional distribution and underlying pathology of myelinated T2 lesions were investigated in postmortem MCMS brains. Postmortem brain slices from previously characterized MCMS (10 cases) and typical MS (TMS) cases (12 cases) were co-registered with in situ postmortem T2 hyperintensities and T1 hypointensities. T1 intensity thresholds were used to establish a classifier that differentiates MCMS from TMS. The classifier was validated in 36 uncharacterized postmortem brains and applied to baseline MRIs from 255 living PMS participants enrolled in SPRINT-MS. Myelinated T2 hyperintensities in postmortem MCMS brains have a contiguous periventricular distribution that expands at the occipital poles of the lateral ventricles where a surface-in gradient of myelinated axonal degeneration was observed. The MRI classifier distinguished pathologically confirmed postmortem MCMS and TMS cases with an accuracy of 94%. For SPRINT-MS patients, the MRI classifier identified 78% as TMS, 10% as MCMS, and 12% with a paucity of cerebral T1 and T2 intensities. In SPRINT-MS, expanded disability status scale and brain atrophy measures were similar in MCMS and TMS cohorts. A paucity of cerebral WM demyelination in 22% of living PMS patients raises questions regarding a primary role for cerebral WM demyelination in disability progression in all MS patients and has implications for clinical management of MS patients and clinical trial outcomes in PMS. Periventricular myelinated fiber degeneration provides additional support for surface-in gradients of neurodegeneration in MS.
Patients who fulfilled the selection criteria will be included in the study. One quadrant will be treated with HA gel (test) and the other without to serve as control. Clinical examination will be done in a dental chair under standard conditions of light, using mouth mirror and graduated Williams Periodontal Probe.

All patients will receive full mouth scaling and root planing with hand instruments and ultrasonic scalers at baseline. Thereafter, in the test quadrant, 1 ml of 0.8% hyaluronic acid gel will be administered subgingivally in all selected test sites at baseline and 1 week later. The following clinical parameters will be recorded at baseline, after 6 weeks and 12 weeks post treatment. Oral hygiene instructions will be given to all patients. The clinical measurements and treatment will be performed by a single examiner.For every patient and control subject, GCF samples will be collected at baseline, 6 weeks and 12 weeks post treatment. The samples will be pooled from two periodontal sites with clinical attachment level of 3 mm or more (in the two different quadrants). The sampling area will be isolated with cotton rolls and carefully will be cleaned supragingivally with sterile cotton pellets. A sterile absorbent paper point will be inserted into the gingival crevice or pocket until resistance will be felt. The paper point will be held in place for 30 s and then will be transferred to a vial containing 100 μL of distilled water and vigorously will be mixed. The paper points will be removed, and the samples will be centrifuged and will be washed twice with distilled water. The resultant pellets will be resuspended in 0.4 mL of distilled water. The samples will be coded and stored at -70 °C until use for ELISA test for identification of Human beta Defensin-2.
In this study, the primary aim is to identify the change in the Lactobacillus E. coli ratio within the lower urinary tract, the vagina, and the peri-rectal area in response to an oral probiotic as well as to evaluate the stability of these changes following cessation of an oral probiotic. Voided urine and peri-urethral, vaginal, and peri-rectal swab samples will be analyzed for their Lactobacillus E. coli ratio using bacterial culture as well as 16S ribosomal RNA gene sequencing. The study will compare the ratios present before, during, and after oral probiotic usage. The study will also compare the change in ratios between subjects taking the oral probiotic and those taking an oral placebo.

A secondary aim is to identify the normal daily changes (i.e. stability) in the bacterial populations within the voided urine, including whether host intrinsic (e.g. diet, hygiene, and sexual activity) and extrinsic (e.g. menstruation) factors affect the stability of bacterial populations. The bacterial populations defining the voided urine samples will be correlated to various daily subject-reported lifestyle variables. These include diet, hygiene, sexual activity, medication usage, alcohol usage, menstruation, and urinary-related symptoms. These lifestyle variables will be recorded each day for the entire duration of the study.
Vitamin C is an important micronutrient for human. Association between vitamin C and trouble sleeping was less studied. Therefore, the purpose of this study was to investigate the possible link between vitamin C in serum and trouble sleeping. The cross-sectional data was derived from the National Health and Nutrition Examination Survey (NHANES, 2017-2018). Trouble sleeping was measured by asking participants: "Have you ever told doctor had trouble sleeping". Responses to this question was "yes" or "no". vitamin C in serum was obtained by measuring the serum samples. We used multivariable binary logistic regressions to examine the possible link between vitamin C in serum and trouble sleeping, and then a subgroup analysis was performed. Moreover, the non-linear relationship between vitamin C in serum and trouble sleeping was further detected using a restricted cubic spline (RCS) model. A total of 3227 participants were included in the study. After adjusting all potential confounders, the results of multivariable logistic regression showed the significant negative association between vitamin C in serum and trouble sleeping(OR = 0.816; 95% CI:0.669 ~ 0.995). The significant inverse association was also found in female(OR = 0.713; 95% CI:0.546 ~ 0.931), age ≤ 65 years(OR = 0.773; 95% CI:0.600 ~ 0.996), and in participants with high cholesterol level(OR = 0.738; 95% CI:0.548 ~ 0.994). In addition, the RCS model demonstrated the significant non-linear relationship between vitamin C in serum and trouble sleeping (P value of nonlinear = 0.010). Our study demonstrates the significant negative association between vitamin C in serum and trouble sleeping.
Fondaparinux 5mg subcutaneously 6 hours following surgery, fondaparinux 5mg subcutaneously once daily during hospitalization. Patients will be encouraged to ambulate and compression stockings while in bed.
Patients with persistent knee pain resistant to conservative management for at least 9 months after total knee arthroplasty (TKA) will receive geniculate artery embolization (GAE) using Embozene Color-Advanced Microspheres. Treatment will be completed during one interventional session.
Seretide® Evohaler® 25 microgram /50 microgram per metered dose pressurised inhalation, suspension. 25 micrograms of salmeterol (as salmeterol xinafoate) and 250 micrograms of fluticasone propionate. This is equivalent to a delivered dose (ex actuator) of 21 micrograms of salmeterol and 220 micrograms of fluticasone propionate. 2 puffs twice daily for 12 weeks Phase 1.
Obesity is a pandemic of the 21st century, and the prevalence of this metabolic condition has enormously increased over the past few decades. Obesity is associated with a number of comorbidities and complications, such as diabetes and cardiovascular disorders, which can be associated with severe and fatal outcomes. Adipose tissue is an endocrine organ that secretes numerous molecules and proteins that are capable of modifying immune responses. The progression of obesity is associated with adipose tissue dysfunction, which is characterised by enhanced inflammation and apoptosis. Increased fat-tissue mass is associated with the dysregulated secretion of substances by adipocytes, which leads to metabolic alterations. Importantly, the adipose tissue contains immune cells, the profile of which changes with the progression of obesity. For instance, increasing fat mass enhances the presence of the pro-inflammatory variants of macrophages, major sources of tumour necrosis factor α and other inflammatory mediators that promote insulin resistance. The pathogenesis of obesity is complex, and understanding the pathophysiological mechanisms that are involved may provide novel treatment methods that could prevent the development of serious complications. The aim of this review is to discuss current evidence describing the involvement of various inflammatory mediators in the pathogenesis of obesity.
Aziridines may be subjeted to a cyclooligomerization reaction to produce polyazacycloalkane compounds useful for example in the preparation of chelating agents for use in diagnostic imaging contrast agents. N-benzyl-aziridine in particular is useful as it can be cyclotetramerized and debenzylated to yield cyclen, a key intermediate in chelating agent preparation. The invention provides a particularly attractive route to production of N-benzyl and other N-arylmethyl aziridines of formula (I)where each R1 is independently hydrogen or a group AR and Ar is an optionally substituted phenyl group. The process comprises reacting a purified N-arylmethylethanolamine-sulphonate sulphonate ester with a base. N-aryimethyl-ethanolamine sulphonate ester of the formula R'NHCH2CH2OSO3H, wherein the N-arylmethyl group R' is an N-(bisarylmethyl) or N-(triarylmethyl) group, as intermediates. In a further aspect, the invention provides compounds of formula (II)where Ar and R1 are as hereinabove defined and at least two differing ArCHR21 moieties are present.
Disclosed is a hydrogel composition comprising: 0.01-1.5 wt% of locust bean gum, 0.01-2.0 wt% of xanthan gum, 0.01-1.0 wt% of agar, 1-50 wt% of a component selected from glycerin, butylglycol, propylene glycol, dipropylene glycol, and isopropylene glycol, 0.01-3.0 wt% of a preservative, 0.1-20 wt% of a cosmetic component, and 30-90 wt% of water. The present invention provides a hydrogel sheet product in which a hydrogel layer produced by the hydrogel composition is coated on a liquid lower current layer. The hydrogel composition of the present invention does not include an acrylic polymer but includes only a natural polymer gelating agent, so sherbet-type hydrogel is produced. When being attached to skin, the hydrogel composition is smoothly closely placed on skin. A using sensation is excellent, and moisture included in hydrogel is not leaked to the outside while being circulated, so a moisture leakage stability is excellent and moisture and cosmetic component transferring power are also excellent when the hydrogel composition is attached on skin. Moreover, the hydrogel sheet product of the present invention has a structure in which a liquid lower current layer made of paper or a nonwoven fabric is formed in the opposite surface of a skin attachment surface of the hydrogel layer, so a moisture leakage stability is remarkably improved and power for transferring moisture and cosmetic components to skin is excellently maintained.
This group will only complete online surveys that match the time when intervention group is complete the surveys. There is a baseline survey and then a post-survey 6 weeks later for both educators and students. Additionally, students will complete a 6- and 12-month follow-up survey.
This disclosure is directed to compositions comprised of antimicrobial peptides (AMPs) having an alpha helical structure wherein one side is highly hydrophobic. Representative sequences of the antimicrobial peptides include ILKKWWββαβGLLGβLLGαVββVIKβLββI (SEQ ID No. 2), LKKWWKβαKGLLGGLLGKVββVIK (SEQ ID No. 12), and αKKααKKαKGαLGGLαGK (SEQ ID No. 18). Additional embodiments disclose methods for treating a microbial infection; reducing biofilm; decreasing inflammation; and treating infectious diseases, COPD, asthma, pulmonary fibrosis, cystic fibrosis, rhinosinusitis, septicemia, RSV, TB or cancer; in a subject in need thereof comprising administering to the subject a therapeutic amount of an antimicrobial peptide.
The present invention discloses injectable inorganic bone cement for in situ solidification and application thereof in minimally invasive treatment. A substance with a shielding action to X rays is mixed with solid powder of the inorganic bone cement for in situ solidification by the present invention, and is infused into a pressure injector after being uniformly proportioned with solidifying liquid to become a viscous pasty object. A pathologically changed corpus vertebra is percutaneously punctured under the assistance of fluoroscopic guidance equipment. The pasty object is injected into the corpus vertebra so as to solidify automatically in a human body environment. Compared with the prior art, the present invention has the characteristics of 'optional moulding, automatic solidification, biocompatibility and gradual degradation'. The effects of fixed-point injection and in situ solidification can be achieved. The flow states of slurry are stably changed in the process of solidification. The present invention has the advantages of superior flowability, low viscosity and great permeability. Thus, operation is more convenient, biocompatibility and biosafety are much better than those of PMMA, complications are fewer, and the characteristics of materials can be changed according to the difference of clinical use requirements within a certain range so as to serve patients better.
The first British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS)-endorsed faecal microbiota transplant (FMT) guidelines were published in 2018. Over the past 5 years, there has been considerable growth in the evidence base (including publication of outcomes from large national FMT registries), necessitating an updated critical review of the literature and a second edition of the BSG/HIS FMT guidelines. These have been produced in accordance with National Institute for Health and Care Excellence-accredited methodology, thus have particular relevance for UK-based clinicians, but are intended to be of pertinence internationally. This second edition of the guidelines have been divided into recommendations, good practice points and recommendations against certain practices. With respect to FMT for Clostridioides difficile infection (CDI), key focus areas centred around timing of administration, increasing clinical experience of encapsulated FMT preparations and optimising donor screening. The latter topic is of particular relevance given the COVID-19 pandemic, and cases of patient morbidity and mortality resulting from FMT-related pathogen transmission. The guidelines also considered emergent literature on the use of FMT in non-CDI settings (including both gastrointestinal and non-gastrointestinal indications), reviewing relevant randomised controlled trials. Recommendations are provided regarding special areas (including compassionate FMT use), and considerations regarding the evolving landscape of FMT and microbiome therapeutics.